Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Large Growth in Short Interest

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 80,400 shares, a growth of 28.2% from the September 30th total of 62,700 shares. Currently, 1.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 40,100 shares, the short-interest ratio is currently 2.0 days.

Matinas BioPharma Stock Performance

Shares of MTNB traded down $0.86 during mid-day trading on Wednesday, reaching $1.93. 154,917 shares of the company’s stock traded hands, compared to its average volume of 30,504. The stock has a market cap of $9.69 million, a price-to-earnings ratio of -0.47 and a beta of 1.64. Matinas BioPharma has a 12 month low of $1.90 and a 12 month high of $21.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Towercrest Capital Management purchased a new stake in shares of Matinas BioPharma during the second quarter worth $299,000. Alliance Wealth Management Group acquired a new position in shares of Matinas BioPharma during the second quarter worth $299,000. Finally, Highbridge Capital Management LLC acquired a new position in Matinas BioPharma in the second quarter valued at $1,685,000. 11.77% of the stock is currently owned by institutional investors and hedge funds.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.